Johnson & Johnson

JNJ · NYSE · ·

下次财报：2026年10月13日 · 开盘前

US$267.55-1.6%9月29日收盘

1M: -0.2%
6M: +11.5%
1Y: +47.5%
5Y: +88.5%

Makes prescription medicines and medical devices for cancer, immune disorders, surgery, heart care, joint replacement and vision.

Johnson & Johnson（JNJ）股票——这是一门好生意吗？ — InspectStocks

Johnson & Johnson

JNJ · NYSE · ·

下次财报：2026年10月13日 · 开盘前

US$267.55-1.6%9月29日收盘

1M: -0.2%
6M: +11.5%
1Y: +47.5%
5Y: +88.5%

对比

Makes prescription medicines and medical devices for cancer, immune disorders, surgery, heart care, joint replacement and vision.

怎么赚钱

Innovative Medicine64%
MedTech36%

各项收入占比是对six months ended June 28, 2026, high confidence的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

DARZALEX
A medicine used to treat multiple myeloma, a cancer of plasma cells.
TREMFYA
A medicine for conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
CARVYKTI
A treatment made from a patient’s modified immune cells for multiple myeloma that has returned or has not responded to earlier treatment.

再显示 3 项

VARIPULSE
A system that uses pulsed electrical energy to treat atrial fibrillation, a disorder that causes an irregular heartbeat.
Impella
A heart pump used to support blood circulation in certain patients with heart failure or during high-risk heart procedures.
ACUVUE
A brand of contact lenses sold for vision correction.

谁在买4

Wholesalers, distributors and retailers that buy medicines and medical products for resale.
Hospitals and clinics that buy medicines and devices for patient care and procedures.
Physicians and other healthcare professionals who prescribe medicines or use medical devices in treatment.
Eye-care professionals and retailers that supply contact lenses and other vision products.

靠什么支撑，什么会击垮它

业务依赖什么

1Some medicines rely on licenses or partnerships with other companies. For example, a subsidiary licenses patent families related to DARZALEX from Genmab, and IMBRUVICA is co-commercialized in the United States with Pharmacyclics, an AbbVie company.
2The company depends on government approvals and ongoing oversight for its medicines and medical devices, including rules on safety, manufacturing, labeling and sales.
3Sales depend partly on health insurers and government programs deciding whether to cover products and how much they will reimburse; U.S. and other governments can also change medicine-pricing rules.
4The company uses third parties to make or supply some products and relies on complex international manufacturing and distribution chains.

可能出什么问题

1Generic and biosimilar competition can reduce sales of medicines when alternatives enter the market. The latest quarterly report describes continuing sales declines for STELARA and says biosimilar competition is also affecting other medicines.
2Government pricing rules, coverage decisions and reimbursement changes can affect what the company receives for medicines and medical devices. The company identifies U.S. drug-pricing measures and tighter regulation across markets as concerns.
3Lawsuits and product-safety claims can lead to substantial costs and affect sales or reputation. The latest quarterly report recorded charges related to talc litigation.

完整财务报表 →

与同行业相比处在什么位置

三项评分，每一项都是相对我们在Drug Manufacturers General覆盖的 21 家公司的百分位。刻意分开而不揉成一个总分：便宜、上涨和经营得好是三件不同的事，一个数字会把它们是哪一件藏起来。

动量

84在同行业中满分 100

接近同行业顶部

截至一个月前的 12 个月54.7%

截至一个月前的 6 个月9.0%

最近一个月被刻意剔除：回报往往在 7 到 12 个月内延续，而最新的一个月往往反转。这描述的是股价已经走过的路，不说明它接下来会怎么走。

估值

24在同行业中满分 100

低于行业内多数公司

每单位价格对应的利润3.26%

每单位价格对应的现金3.45%

每单位价格对应的营收15.19%

每单位价格对应的资产12.65%

整个企业对应的经营利润3.77%

这些是收益率，所以数值越高越便宜——亏损的公司会排在最后，而不是被剔除。便宜不等于好：高收益率往往意味着股价是有原因才跌下来的。五项指标齐全。

资本配置

5/5克制

1 项检验未披露

资本回报率12.7%

股东回报率0.92%

股本数量，3 年-9.5%

净债务 / EBITDA1.23x

内部人，12 个月-US$84.4M

管理层怎么使用这笔钱——只按财报能回答的部分计分，绝不按占总数的比例计分。

六项资本配置检验

投入资金的回报投入资本回报 12.7%
债务与盈利之比净债务为经营利润的 1.23 倍
回馈给股东的现金每年 0.9% 用于回购和分红
三年间的股本数量三年间股本数量减少 9.5%
现金流对派付的覆盖自由现金流覆盖了派付的部分
内部人在公开市场的买入净卖出 US$84.4M——不计入扣分

这是对该公司在同行中所处位置的描述，不是投资建议。评分更新于 2026年9月30日。

关于Johnson & Johnson

Johnson & Johnson develops, makes and sells prescription medicines and medical devices around the world. Its two businesses are Innovative Medicine, which sells medicines for conditions including cancer and immune disorders, and MedTech, which sells products used in heart procedures, surgery, orthopaedics and vision care.

总部: New Brunswick, New Jersey
成立于: 1887 (founding year, high confidence)
员工人数: 140,800 (December 28, 2025, high confidence)
上市于: New York Stock Exchange
财年结束: Last Sunday in December

基于 Johnson & Johnson 自己向 SEC 提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。

怎么赚钱

Innovative Medicine64%
MedTech36%

各项收入占比是对six months ended June 28, 2026, high confidence的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

DARZALEX
A medicine used to treat multiple myeloma, a cancer of plasma cells.
TREMFYA
A medicine for conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
CARVYKTI
A treatment made from a patient’s modified immune cells for multiple myeloma that has returned or has not responded to earlier treatment.

再显示 3 项

VARIPULSE
A system that uses pulsed electrical energy to treat atrial fibrillation, a disorder that causes an irregular heartbeat.
Impella
A heart pump used to support blood circulation in certain patients with heart failure or during high-risk heart procedures.
ACUVUE
A brand of contact lenses sold for vision correction.

谁在买4

Wholesalers, distributors and retailers that buy medicines and medical products for resale.
Hospitals and clinics that buy medicines and devices for patient care and procedures.
Physicians and other healthcare professionals who prescribe medicines or use medical devices in treatment.
Eye-care professionals and retailers that supply contact lenses and other vision products.

靠什么支撑，什么会击垮它

业务依赖什么

1Some medicines rely on licenses or partnerships with other companies. For example, a subsidiary licenses patent families related to DARZALEX from Genmab, and IMBRUVICA is co-commercialized in the United States with Pharmacyclics, an AbbVie company.
2The company depends on government approvals and ongoing oversight for its medicines and medical devices, including rules on safety, manufacturing, labeling and sales.
3Sales depend partly on health insurers and government programs deciding whether to cover products and how much they will reimburse; U.S. and other governments can also change medicine-pricing rules.
4The company uses third parties to make or supply some products and relies on complex international manufacturing and distribution chains.

可能出什么问题

1Generic and biosimilar competition can reduce sales of medicines when alternatives enter the market. The latest quarterly report describes continuing sales declines for STELARA and says biosimilar competition is also affecting other medicines.
2Government pricing rules, coverage decisions and reimbursement changes can affect what the company receives for medicines and medical devices. The company identifies U.S. drug-pricing measures and tighter regulation across markets as concerns.
3Lawsuits and product-safety claims can lead to substantial costs and affect sales or reputation. The latest quarterly report recorded charges related to talc litigation.

完整财务报表 →

与同行业相比处在什么位置

动量

84在同行业中满分 100

接近同行业顶部

截至一个月前的 12 个月54.7%

截至一个月前的 6 个月9.0%

最近一个月被刻意剔除：回报往往在 7 到 12 个月内延续，而最新的一个月往往反转。这描述的是股价已经走过的路，不说明它接下来会怎么走。

估值

24在同行业中满分 100

低于行业内多数公司

每单位价格对应的利润3.26%

每单位价格对应的现金3.45%

每单位价格对应的营收15.19%

每单位价格对应的资产12.65%

整个企业对应的经营利润3.77%

资本配置

5/5克制

1 项检验未披露

资本回报率12.7%

股东回报率0.92%

股本数量，3 年-9.5%

净债务 / EBITDA1.23x

内部人，12 个月-US$84.4M

管理层怎么使用这笔钱——只按财报能回答的部分计分，绝不按占总数的比例计分。

六项资本配置检验

投入资金的回报投入资本回报 12.7%
债务与盈利之比净债务为经营利润的 1.23 倍
回馈给股东的现金每年 0.9% 用于回购和分红
三年间的股本数量三年间股本数量减少 9.5%
现金流对派付的覆盖自由现金流覆盖了派付的部分
内部人在公开市场的买入净卖出 US$84.4M——不计入扣分

这是对该公司在同行中所处位置的描述，不是投资建议。评分更新于 2026年9月30日。

关于Johnson & Johnson

总部: New Brunswick, New Jersey
成立于: 1887 (founding year, high confidence)
员工人数: 140,800 (December 28, 2025, high confidence)
上市于: New York Stock Exchange
财年结束: Last Sunday in December

怎么赚钱

竞争对手

卖什么6

谁在买4

靠什么支撑，什么会击垮它

业务依赖什么

可能出什么问题

与同行业相比处在什么位置

关于Johnson & Johnson

怎么赚钱

竞争对手

卖什么6

谁在买4

靠什么支撑，什么会击垮它

业务依赖什么

可能出什么问题

与同行业相比处在什么位置

关于Johnson & Johnson

成长与现金——5 项中通过 5 项